Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.
EP. 1: Overview of Metastatic Uveal Melanoma
Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.
EP. 2: Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma
Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.
EP. 3: Recent Trial Data on Tebentafusp in Metastatic Uveal Melanoma
Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.
EP. 4: Managing Tebentafusp Toxicities in Metastatic Uveal Melanoma
Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.
EP. 5: Future Directions in Metastatic Uveal Melanoma Treatment
Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis